Lege Artis Medicinae

[The 50th Anniversary of the Helsinki Declaration: Commentary to the 2013 Amendment ]

DOMJÁN Andrea, KAKUK Péter, SÁNDOR Judit

MARCH 20, 2014

Lege Artis Medicinae - 2014;24(03)

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[World Medical Association Declaration of Helsinki (WMA) - Ethical principles for medical research involving human subjects]

DOMJÁN Andrea, KAKUK Péter, SÁNDOR Judit

Lege Artis Medicinae

[Crucial points in the therapy of hepatitis C]

MAKARA Mihály, HUNYADY Béla

[The first generation of direct acting antivirals represented a milestone in the therapy of hepatitis C but other breakthroughs are on the way with imminent authorization of new antiviral drugs and interferon-free combinations. The prices of these new agents necessitate the rational use of limited financial capacities: relatively cheaper interferon-based treatments could be used first for those who can be cured with these combinations, while the most expensive treatments are to be reserved for those with no other options. In the future, interferonfree regimens will likely be used first in those patients who did not respond to firstgeneration interferon-based regimens and in whom interferon therapy is contraindicated. To avoid complications of the disease, currently it is reasonable to treat all eligible patients with advanced fibrosis, particularly those with compensated cirrhosis, with interferon-based treatments. In some instances other medical or social conditions warrant prompt treatment. The triage of treatments is based on the Priority Index in Hungary. Current triple therapies with protease inhibitors are complicated by drug and food interactions as well as by frequent (sometimes severe) side effects. General practitioners and other specialists need to be involved in managing these issues. It is of utmost importance to refer patients to hepatology care before decompensation or development of hepatocellular carcinoma. The key of timely and accurate diagnosis is organized anti-HCV screening in populations at risk and in the age group with the highest prevalence.]

Lege Artis Medicinae

[“I am Most Interested by the Special Surgery Problems which Seem to be Unresolvable” – An Interview with Gábor Vogt MD ]

FERENCZI Andrea

Lege Artis Medicinae

[Meet the new member of the alprazolam family]

FERENCZ Csaba

[The struggle against anxiety disorders and symptoms of anxiety is as old as the history of human healing. The development of anxiolytics has constituted an important field of pharmacology from the very beginning. The appearance of benzodiazepines and high-potential benzodiazepines, developed as a later evolution of the former compounds, is considered a milestone in this battle. Today alprazolam is their most widely-used representative that can be considered a golden standard. Besides its agent, the formulation of the drug is also significant, as it helps in the administration, absorption and bioavailability of the agent and even for the establishment of good compliance. Nowadays we can witness the development of medicine families containing the same active ingredient and consisting of various products. In the case of alprazolam, we can welcome a new member of the family following the immediate-release tablets and the extended-release tablets. The aim of this paper is the introduction of the new member of the alprazolam family: the sublingual tablet.]

Lege Artis Medicinae

[The Ophthalmology Professor of the University of Kharkiv]

MOLNÁR László

All articles in the issue

Related contents

Lege Artis Medicinae

[Some thoughts at the 50th anniversary of my medical graduation]

BOGA Bálint

Lege Artis Medicinae

[Requiem - For the fiftieth anniversary of the foundation of the Institute for Postgraduate Medical Education]

FORGÁCS Iván

Hypertension and nephrology

[Serum uric acid level in hypertension. Domestic experience based on the data of the Hungarian Hypertension Registry 2011., 2013. and 2015. Part III. - Relation of uric acid to clinical and laboratory characteristics]

KÉKES Ede, PAKSY András, ALFÖLDI Sándor

[2013. and 2015, we examined the correlation between the serum uric acid level and blood pressure, target blood pressure, prevalence of ISH and other diseases associated to high blood pressure used trend analysis and linear regression in 22,668 hypertensive men (mean age 60.8 years) and 24,684 hypertensive women (mean age 64.1 years). We have extended the correlation analysis to metabolic factors (BMI, abdominal circumference, lipid profile, blood sugar) and kidney function. Significant correlation was found between SH level and systolic and diastolic blood pressure as well as target blood pressure. There was a significant correlation between SH level and metabolic parameters (abdominal circumference, BMI, total cholesterol, HDL cholesterol, triglyceride, fasting blood sugar) and in hyperuricemia the prevalence of metabolic syndrome was higher. As the level of SH increases, the prevalence of hypertension-related KVB, ISZB and diabetes have increased. The closest correlation between uric acid levels and chronic kidney disease was in women and between the uric acid levels and ischemic heart disease in men. ur analysis supports the international declaration that hyperuricemia is an independent cardiovascular, metabolic and renal risk factor.]

Lege Artis Medicinae

[Editor’s Commentary to Attila Bánfalvi’s Publication ‘The Faith of Faithlessness’ ]

KAPÓCS Gábor

Lege Artis Medicinae

[SOME ETHICAL DILEMMAS OF PLACEBO-CONTROLLED STUDIES]

KOVÁCS József

[The article deals with the question where and when is it ethically acceptable in a randomized controlled clinical trial to give the investigational drug to one of the groups, while placebo to the other. First, it gives a short overview on the origin of the problem and the history of its reemergence before and after the revision of the Declaration of Helsinki 2000. It examines the various forms of placebo use, the pros and cons of its implementation, the international debate before the revision of the Declaration of Helsinki 2000 and the corrections after its acceptance. Finally it declares some principles in connection with placebo controlled clinical trials and examines when such a trial is acceptable in various psychiatric disorders.]